结核分枝杆菌对吡嗪酰胺的耐药性出现在对利福平和氟喹诺酮耐药之后。
Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
作者信息
Alame-Emane A K, Xu P, Pierre-Audigier C, Cadet-Daniel V, Shen X, Sraouia M, Siawaya J F Djoba, Takiff H, Gao Q, Gicquel B
机构信息
Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Research and Specialised Diagnostics Unit, National Laboratory of Public Health, Libreville, Gabon.
Key Laboratory of Medical Molecular Virology, Institutes of Biomedical Sciences and Institute of Medical Microbiology, Shanghai Medical College, Fudan University, Shanghai, China.
出版信息
Int J Tuberc Lung Dis. 2015 Jun;19(6):679-84. doi: 10.5588/ijtld.14.0768.
BACKGROUND
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern.
OBJECTIVE
To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP).
DESIGN
Isolates from two major urban centres--Paris (101 strains) and Shanghai (171 strains)--were investigated for the association of pncA mutations with resistance to drugs other than PZA.
RESULTS
The proportion of pncA mutations found in INH-monoresistant strains was not increased.
CONCLUSION
pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.
背景
结核分枝杆菌的多重耐药（MDR）和广泛耐药（XDR）菌株是主要的公共卫生问题。
目的
确定赋予吡嗪酰胺（PZA）耐药性的pncA突变相对于赋予异烟肼（INH）和利福平（RMP）耐药性的突变的发生时间。
设计
对来自两个主要城市中心——巴黎（101株）和上海（171株）的分离株进行研究，以探讨pncA突变与对PZA以外其他药物的耐药性之间的关联。
结果
在仅对INH耐药的菌株中发现的pncA突变比例没有增加。
结论
与PZA耐药相关的pncA突变几乎仅在耐多药结核菌株中发现，这突出了在治疗耐多药或广泛耐药结核病时确定PZA耐药性的重要性。
Zotero 插件